Allen Feng

Biography

 Dr. Allen Feng is the Chief Scientific Officer of VcanBio CTB and HebeCell Corp. Prior to joining VcanBio,  he was the Director of Cell Biology of Semma Therapeutics, where Dr. Feng played a key role in the successful establishment of the process development operation. Prior to Semma, Dr. Feng worked as R&D Head of Stem Cell Bioprocessing Group at EMD Millipore (a US subsidiary of Merck, KGaA). Before joining Millipore, Dr. Feng was Director and Senior Scientist at Advanced Cell Technology (later became Ocata Therapeutics and Astellas). At Advanced Cell Technology, Dr. Feng was the major contributor and inventor of several key discoveries such as the patented Hemangioblast technology (published in Nature Methods); generation of donorless red blood cells (published in Blood); and generation of HLA-negative functional platelets from human pluripotent stem cells (published in Stem Cell Reports).   Dr. Feng graduated with a Ph.D and an M.S. degree from Institute of Zoology at Chinese Academy of Sciences. He earned his B.S. degree from Beijing Normal University. He was the Associate Professor and the Deputy Director of the State Key Laboratory of Reproductive Biology in Chinese Academy of Sciences. Dr. Feng received the prestigious award of Wu Jie-ping Medical Research Award and the Paul Janssen Pharmaceutical Research Award in 1995, as well as the Fellowship of Marie-Curie of the European Union and the Wellcome Trust (U.K)

Research Interest

 Cell Biology, Reproductive Biology, Pharmacology